Loading stock data…
HUM
$363.11+7.13 (+2.00%)
Market OpenUpdated 3:47 PM EDT
Humana Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Humana Inc. in the Healthcare sector is trading at $363.11 with a market capitalization of $39.3B. Wall Street consensus targets $290.08 (24 analysts), implying a -20.1% move over the next 12 months. The stock is currently near its 52-week high of $364.38, remaining 48.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -20.1% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$363.11
Potential Downside
39.3%
Whystock Fair Value$220.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Hold
Mean target$290.08-20.1%
Range$195.00 – $441.00
Fundamentals
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$39.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
34.96
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.98%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.08%
Volume
Today's trading volume
870,457
Recent News
Illinois awards new Medicaid contracts
The state said it intends to divvy out new contracts, which represent tens of billions of dollars in revenue for each awardee, to six insurers. Winners are mostly incumbents, except for Humana.
Forget AI: Billionaire Stanley Druckenmiller Likes This Insurance Stock
We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. Humana Inc. (NYSE:HUM) ranks #9 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller). Druckenmiller’s Stake: $23,842,000 Humana Inc. (NYSE:HUM) is a US health insurer focused mainly on Medicare Advantage plans for seniors. While the stock is […]
Is Humana Stock Outperforming the Nasdaq?
Humana has rallied the Nasdaq Composite over the past year, and analysts remain moderately bullish about the stock’s outlook.
2 Surging Stocks to Own for Decades and 1 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Humana (HUM) Valuation Check After Launch Of New CenterWell Pharmacy Distribution Center
Humana (HUM) is drawing fresh attention after opening full operations at its new US$83 million CenterWell Pharmacy mail order distribution center in Orlando, Florida, expanding prescription delivery capacity across the region. See our latest analysis for Humana. The stock's recent momentum has been strong, with a 30 day share price return of 42.12% and a 1 year total shareholder return of 54.14%, even though the 3 and 5 year total shareholder returns remain in decline. Some investors may link...